brexucabtagene autoleucel
gilead
['tecartus']
tecartus was approved for relapsed/refractory b-cell all in october 2021, and since then has become an impressive standard of care option for this patient population, research from #asco23 showed. 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.